联合抗血小板治疗对直接口服抗凝药治疗急性静脉血栓栓塞疗效与安全性的影响:系统评价与荟萃分析
结果显示联合抗血小板治疗未降低复发性静脉血栓栓塞及静脉血栓栓塞相关死亡风险,但显著增加大出血风险。
要点
- 联合抗血小板治疗未降低复发性静脉血栓栓塞及静脉血栓栓塞相关死亡风险。
- 联合抗血小板治疗使大出血风险增加约1.8倍。
- 在接受抗血小板治疗的患者中,直接口服抗凝药与维生素K拮抗剂的疗效和安全性无显著差异。
核心结论
- 联合使用抗血小板治疗与口服抗凝药似乎不影响复发性静脉血栓栓塞风险,但增加大出血风险。
主要发现
- 3550例(13.2%)接受联合抗血小板治疗,其中阿司匹林占67.7%。
- 联合抗血小板治疗未降低复发性静脉血栓栓塞及静脉血栓栓塞相关死亡风险:任何口服抗凝药OR 1.17(95%CI 0.92-1.48),直接口服抗凝药OR 1.21(95%CI 0.86-1.71),维生素K拮抗剂OR 1.16(95%CI 0.77-1.73)。
- 联合抗血小板治疗增加大出血风险:任何口服抗凝药OR 1.79(95%CI 1.22-2.63),直接口服抗凝药OR 1.89(95%CI 1.04-3.44),维生素K拮抗剂OR 1.73(95%CI 1.16-2.59)。
- 在接受联合抗血小板治疗的患者中,直接口服抗凝药与维生素K拮抗剂的疗效和安全性无显著差异:疗效OR 0.99(95%CI 0.64-1.51),安全性OR 0.68(95%CI 0.32-1.45)。
临床怎么用
- 对于接受口服抗凝药治疗的急性静脉血栓栓塞患者,应谨慎评估联合抗血小板治疗的必要性,因其不减少复发事件但增加大出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct oral anticoagulants (DOACs) are recommended over vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). Concomitant antiplatelet therapy may potentiate the antithrombotic effects of DOACs. OBJECTIVES: We evaluated the impact of concomitant antiplatelet therapy on the efficacy and safety of DOACs. PATIENTS/METHODS: MEDLINE, EMBASE, and Clinicaltrial.gov were searched for randomized controlled trials of DOACs for the treatment of acute VTE. The efficacy outcome was symptomatic recurrent VTE and VTE-related death; the primary safety outcome was major bleeding. RESULTS: Six randomized controlled trials included 26 924 patients of whom 3550 (13.2%) received concomitant antiplatelet therapy, mainly aspirin (67.7%). Concomitant antiplatelet therapy did not reduce the incidence of recurrent VTE and VTE-related death with any oral anticoagulant (odds ratio [OR] 1.17; 95% confidence interval [CI], 0.92-1.48), with DOACs (OR 1.21; 95% CI, 0.86-1.71), or VKAs alone (OR 1.16; 95% CI, 0.77-1.73). Compared with no antiplatelet therapy, concomitant antiplatelet therapy was associated with a higher risk of major bleeding in patients with any oral anticoagulant (OR 1.79; 95% CI, 1.22-2.63), DOACs (OR 1.89; 95% CI, 1.04-3.44), or VKAs (OR 1.73; 95% CI, 1.16-2.59). In patients receiving concomitant antiplatelet therapy, there were no statistically significant differences in efficacy or safety outcomes with DOACs or VKAs (OR 0.99; 95% CI, 0.64-1.51, and OR 0.68; 95% CI, 0.32-1.45, respectively). CONCLUSIONS: Concomitant use of antiplatelet therapy with oral anticoagulants does not appear to affect the risk of recurrent VTE and increases the risk of major bleeding.
引用
- Valeriani E, Porreca E, Weitz JI, et al. Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. J Thromb Haemost. 2020. PMID: 32202042. doi:10.1111/jth.14807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。